Breast Cancer-targets And Therapy SCIE

國際簡稱：BREAST CANCER-TARGET 參考譯名：乳腺癌-靶點(diǎn)和治療

主要研究方向：ONCOLOGY 非預(yù)警期刊審稿周期： 16 Weeks

《乳腺癌-靶點(diǎn)和治療》(Breast Cancer-targets And Therapy)是一本由Dove Medical Press出版的以O(shè)NCOLOGY為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預(yù)警名單。

4區(qū) 中科院分區(qū)
Q2 JCR分區(qū)
75 年發(fā)文量
3.3 IF影響因子
開放是否OA
1 issue/year 出版周期
English 出版語言

"Breast Cancer: Targets and Therapy," with its open-access nature, provides a valuable resource for medical researchers, clinicians, and patients with breast cancer. The journal covers comprehensive research from basic biological mechanisms to clinical applications, committed to promoting innovation and progress in the field of breast cancer treatment.

The journal pays special attention to precision medicine and personalized treatment plans, emphasizing in-depth research on molecular targets of breast cancer and how to translate these research findings into effective clinical treatments. In addition, the journal encourages the publication of research on new drug development, drug sensitivity, resistance mechanisms, and new therapeutic technologies, aiming to provide more treatment options for patients with breast cancer.

[ 查看全部 ]

投稿咨詢加急咨詢

Breast Cancer-targets And Therapy期刊信息

ISSN：1179-1314
出版語言：English
是否OA：開放
E-ISSN：1179-1314
出版地區(qū)：United Kingdom
是否預(yù)警：否
出版商：Dove Medical Press
出版周期：1 issue/year
開源占比：0.9752
Gold OA文章占比：98.22%
OA被引用占比：1
出版國人文章占比：0.03
出版撤稿占比：
研究類文章占比：77.33%

Breast Cancer-targets And Therapy CiteScore評(píng)價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

4.1

0.933

1.009

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Oncology	Q3	203 / 404	49%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評(píng)論、會(huì)議論文、書籍章節(jié)和數(shù)據(jù)論文。

Breast Cancer-targets And Therapy中科院評(píng)價(jià)數(shù)據(jù)

中科院 2023年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

中科院 2022年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

Breast Cancer-targets And Therapy JCR評(píng)價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q2	118 / 322	63.5%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q3	186 / 322	42.39%

Breast Cancer-targets And Therapy歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Breast Cancer-targets And Therapy中國學(xué)者發(fā)文選摘

1、Critical Evaluation of Secondary Cancer Risk After Breast Radiation Therapy with Hybrid Radiotherapy Techniques
Author: Zhang, Quanbin; Zeng, Yu; Peng, Yingying; Yu, Hui; Zhang, Shuxu; Wu, Shuyu

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 25-38. DOI: 10.2147/BCTT.S383369
2、An Magnetic-Targeting Nano-Diagnosis and Treatment Platform for TNBC
Author: Zhang, Mengqi; Bao, Shengxian; Qiu, Guanhua; Liang, Jingchen; Wang, Qin; Zhu, Xiaoqi; Qin, Guchun; Liu, Junjie; Zhao, Chang

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 101-119. DOI: 10.2147/BCTT.S387793
3、Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review
Author: Wu, Jing; Jin, Yudi; Liu, Mei; Zhu, Ningsheng; Jing, Zhouhong; Zeng, Xiaohua

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 39-45. DOI: 10.2147/BCTT.S395944
4、Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
Author: Wang, Jin; Liao, Dongying; Zhang, Xuemin; Miao, Changhong; Chen, Kuang

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 281-294. DOI: 10.2147/BCTT.S407181
5、Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients
Author: Shen, Jun; Yan, Huanhuan; Yang, Congying; Lin, Haiyue; Li, Fan; Zhou, Jun

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 295-310. DOI: 10.2147/BCTT.S402109
6、Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins
Author: Ma, Jing; Dong, Chao; Cao, Yan-Zhen; Ma, Bin-Lin

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 11-24. DOI: 10.2147/BCTT.S390017
7、The Prognostic Role of HuR Varies Between Different Subtypes of Breast Cancer Patients: Data Mining and Retrospective Analysis
Author: Liao, Yuqian; Liao, Yulu; Li, Jun; Li, Yong; Fan, Ying

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 135-146. DOI: 10.2147/BCTT.S395984
8、Optimized Radiomics Nomogram Based on Automated Breast Ultrasound System: A Potential Tool for Preoperative Prediction of Metastatic Lymph Node Burden in Breast Cancer
Author: Li, Ning; Song, Chao; Huang, Xian; Zhang, Hongjiang; Su, Juan; Yang, Lichun; He, Juhua; Cui, Guihua

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 121-132. DOI: 10.2147/BCTT.S398300